m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation

m6A Modification:
Crosstalk ID	M6ACROT05218				[1]
Non-coding RNA miR-532-5p METTL3 lncRNA miRNA circRNA Direct Inhibition m⁶A modification ARHGAP5 ARHGAP5 METTL3 Methylation : m⁶A sites
m6A Regulator	Methyltransferase-like 3 (METTL3)			WRITER	Regulator Info
m6A Target	Rho GTPase activating protein 5 (ARHGAP5)				Targert Gene
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type	Non-coding RNA (ncRNA)
Epigenetic Regulator	hsa-miR-532-5p			microRNA	View Details
Regulated Target	Methyltransferase-like protein 3 (METTL3)				View Details
Crosstalk Relationship	ncRNA → m6A			Inhibition
Crosstalk Mechanism	ncRNAs directly impacts m6A modification through recruiting m6A regulator
Crosstalk Summary	ADAR1 edits METTL3 mRNA and changes its binding site to hsa-miR-532-5p, leading to increased METTL3 protein, which further targets Rho GTPase activating protein 5 (ARHGAP5), recognized by YTHDF1.
Responsed Disease	Breast cancer		ICD-11: 2C60		Disease Info
Cell Process	Proliferation
	migration
	invasion
In-vitro Model	MDA-MB-231	Breast adenocarcinoma	Homo sapiens		CVCL_0062
	T-47D	Invasive breast carcinoma	Homo sapiens		CVCL_0553
	SK-BR-3	Breast adenocarcinoma	Homo sapiens		CVCL_0033
	MCF-7	Invasive breast carcinoma	Homo sapiens		CVCL_0031
In-vivo Model	Roughly 1 × 10⁷ of MCF-7 or MDA-MB-231 cells stably transfected with ADAR1 sgRNA or Ctrl sgRNA (as described above) were injected subcutaneously into the thighs of the female athymic nude mice (5 weeks old, 17-18 g, three mice per group).

Full List of Potential Compound(s) Related to This m6A-centered Crosstalk

2C60: Breast cancer		2 Compound(s) Regulating the Disease	Click to Show/Hide the Full List
Compound Name	Entrectinib		Approved	[2]
Synonyms	1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK Click to Show/Hide
External Link	CID: 25141092 TTD: D0O0LS DrugBank: DB11986
Compound Name	Everolimus		Approved	[3]
External Link	CID: 6442177 TTD: D09ZSC DrugBank: DB01590

References

Ref 1	RNA Editing Enzyme ADAR1 Regulates METTL3 in an Editing Dependent Manner to Promote Breast Cancer Progression via METTL3/ARHGAP5/YTHDF1 Axis. Int J Mol Sci. 2022 Aug 25;23(17):9656. doi: 10.3390/ijms23179656.
Ref 2	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372... Cancer Discov. 2017 Apr;7(4):400-409.
Ref 3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015